ABPI position on mandatory disclosure of clinical data
This article was originally published in Scrip
Scrip asked the UK industry association, the ABPI, if it would support legislation to make it universally obligatory to publish clinical study reports, both new and old, relating to currently available drugs and to those that are in development or have been discontinued. Scrip also asked if ABPI could identify potential problems with such legislation, and propose ideas for avoiding or overcoming them.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.